Publications by authors named "Recher C"
Acute myeloid leukaemia (AML) arising from a myeloproliferative neoplasm (MPN) is more aggressive and less responsive to therapies compared to de novo AML. Olutasidenib, an oral small-molecule inhibitor of mutated IDH1 (mIDH1), showed encouraging and durable responses in a phase 1/2 study of adults with post-MPN mIDH1 AML. Patients received olutasidenib 150 mg BID monotherapy or in combination with azacitidine.
View Article and Find Full Text PDFUnlabelled: This phase 2 study investigated pevonedistat + azacitidine + venetoclax ( = 83) versus azacitidine + venetoclax ( = 81) in patients with newly diagnosed acute myeloid leukemia (AML) ineligible for intensive chemotherapy. The study was stopped early following negative results from PANTHER, which evaluated pevonedistat in higher-risk myelodysplastic syndromes/chronic myelomonocytic leukemia or low-blast AML. Outcomes were analyzed up to the datacut.
View Article and Find Full Text PDFAccording to current recommendations, older AML patients in first complete remission (CR) after induction chemotherapy should receive consolidation with intermediate-dose cytarabine (IDAC). However, no study has demonstrated the superiority of IDAC over other regimen. In this retrospective study, we compared the efficacy of mini-consolidations (idarubicin 8 mg/m day 1, cytarabine 50 mg/m/12 h, day 1-5) and IDAC.
View Article and Find Full Text PDFCPX-351 has been approved for patients with therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (MRC-AML). No extensive data are available on MRD and long-term clinical outcome using CPX-351 in AML in real-life. We retrospectively collected data from 168 patients in 36 centers in France and Italy who had received one or two cycles of induction with CPX-351.
View Article and Find Full Text PDFArticle Synopsis
- Despite initial treatment with midostaurin (MIDO) and chemotherapy in FLT3-mutated acute myeloid leukemia (AML), many patients face relapses, with complete remission rates around 60-70% and over 40% relapsing.
- A study of 150 patients with refractory/relapsed (R/R) AML revealed that those treated with MIDO showed lower persistence of FLT3-ITD mutations compared to those who did not receive MIDO (68% vs. 87.5%).
- The study found that detecting multiple FLT3-ITD clones at diagnosis related to a higher persistence rate of these mutations at relapse, indicating the need for sensitive techniques in FLT3-
Progression or relapse in the central nervous system (CNS) remains a rare but mostly fatal event for patients with diffuse large B-cell lymphoma (DLBCL). In a retrospective analysis of 5189 patients treated within 19 prospective German and French phase 2/3 trials, we identified 159 patients experiencing a CNS event (relapse: 62%, progression: 38%). Intracerebral, meningeal, intraspinal, or combined involvement was reported in 44%, 31%, 3%, and 22% of patients, respectively.
View Article and Find Full Text PDFArticle Synopsis
- The European LeukemiaNet (ELN) classification systems for acute myeloid leukemia (AML) are based on chemotherapy responses and may not effectively predict outcomes for older patients receiving venetoclax-azacitidine.
- A pooled analysis from the phase 3 VIALE-A trial revealed that most patients were classified with adverse-risk AML, yet these classifications did not correlate well with survival outcomes for those treated with venetoclax-azacitidine.
- New molecular signatures based on mutations in TP53, FLT3-ITD, NRAS, and KRAS identified three distinct patient benefit groups, each with significantly different median overall survival times.
Article Synopsis
- Acute myeloid leukemia (AML) is a difficult-to-treat blood cancer, mainly due to the presence of leukemic stem cells (LSCs) that lead to treatment resistance and relapse.
- This research focuses on how the quiescence (dormancy) of LSCs and related molecular mechanisms impact AML development, revealing that quiescent LSCs have a distinct gene signature and increased autophagic activity that helps them survive.
- The study identifies nuclear receptor coactivator 4 (NCOA4) as a key player in iron metabolism for quiescent LSCs, showing that inhibiting NCOA4 can effectively target these cells without harming normal blood progenitors, highlighting its potential as
Patients with Core-Binding Factor (CBF) and NPM1-mutated acute myeloid leukemia (AML) can be monitored by quantitative PCR after having achieved first complete remission (CR) to detect morphologic relapse and drive preemptive therapy. How to best manage these patients is unknown. We retrospectively analyzed 303 patients with CBF and NPM1-mutated AML, aged 18-60 years, without allogeneic hematopoietic cell transplantation (HCT) in first CR, with molecular monitoring after first-line intensive therapy.
View Article and Find Full Text PDFOutcomes in Critically Ill Allogeneic Hematopoietic Stem-Cell Transplantation Recipients.
Am J Respir Crit Care Med
October 2024
Article Synopsis
- A study examined the mortality and factors affecting outcomes for 1,164 patients who underwent allogeneic hematopoietic stem-cell transplantation and were admitted to ICUs in France from 2015 to 2020.
- The findings revealed a 90-day mortality rate of 48%, with higher risks linked to age, time from transplant to ICU admission, and the need for invasive treatments like vasopressors and mechanical ventilation.
- Despite high mortality rates, many critically ill patients who received intensive care did survive their ICU stays, prompting the need for a careful evaluation of treatment options for those with multiple risk factors.
Article Synopsis
- Some JAK inhibitors like ruxolitinib can worsen anemia in myelofibrosis patients; switching to momelotinib may be more beneficial for managing anemia while maintaining symptom control.
- The SIMPLIFY-2 trial compared momelotinib with best available therapy (mostly ruxolitinib) in JAK inhibitor-experienced patients, revealing better transfusion independence rates in those switched to momelotinib.
- Patients with lower baseline hemoglobin levels experienced greater improvements in mean hemoglobin and overall outcomes with momelotinib, suggesting it's a better option for those struggling with anemia.
Article Synopsis
- Venetoclax-azacitidine is the standard treatment for unfit acute myeloid leukemia patients, but there is limited data on how long patients should continue therapy if they cannot tolerate it.
- In a study analyzing patients who stopped treatment due to poor tolerance, those who discontinued showed comparable outcomes to those who continued with azacitidine alone, with median overall survival of 44 months for newly diagnosed patients.
- The findings suggest that patients who stop treatment while in remission can have favorable outcomes, indicating a need for further controlled trials to explore optimal treatment durations.
Article Synopsis
- Acute myeloid leukemia (AML) with BCR::ABL1 is classified as an adverse-risk group in the 2022 ELN classification, but its outcomes with modern treatment options like tyrosine kinase inhibitors are not well understood.
- In a study of 20 patients with de novo BCR::ABL1 AML from a large registry, most received standard chemotherapy with imatinib, leading to a high complete remission rate of 94.4%.
- The survival rates suggest BCR::ABL1 AML patients have better outcomes than those classified in traditional adverse-risk categories, indicating they may need reclassification in future treatment guidelines.
Article Synopsis
- In patients with acute myeloid leukemia (AML), a higher presence of Vγ9Vδ2 T cells at diagnosis is associated with better overall and relapse-free survival rates.
- This study analyzed immunophenotypic data from 198 newly diagnosed AML patients to determine how Vγ9Vδ2 T-cell frequency impacts prognosis while adjusting for various confounding factors.
- The findings support the importance of Vγ9Vδ2 T cells in AML prognosis and suggest potential treatment strategies that could boost these T-cell responses in patients.
The PI3K-AKT-mTOR pathway lies at the confluence of signaling pathways in which various components are subjected to activating genetic alterations in acute myeloid leukemia (AML), thus contributing to oncogenesis. Three AKT isoforms exist in humans. However, whether one isoform predominates in AML remains unknown.
View Article and Find Full Text PDFArticle Synopsis
- Acute myeloid leukemia (AML) with myelodysplasia-related characteristics presents a mixed prognosis, and there's limited understanding of patient outcomes after first-line treatment in refractory or relapsed cases.
- A study involving 183 patients found that the median overall survival was 4.2 months, with no significant survival difference between refractory and relapsed patients; however, patients receiving best supportive care had markedly poorer outcomes.
- The research suggests that both intensive chemotherapy and azacitidine are viable treatment options for this tough-to-treat population, and emphasizes the need for further exploration of new targeted therapies.
Venetoclax-azacitidine is approved for treatment of patients with newly diagnosed acute myeloid leukemia (AML) ineligible for intensive chemotherapy based on the interim overall survival (OS) analysis of the VIALE-A study (NCT02993523). Here, long-term follow-up is presented to address survival benefit and long-term outcomes with venetoclax-azacitidine. Patients with newly diagnosed AML who were ineligible for intensive chemotherapy were randomized 2:1 to receive venetoclax-azacitidine or placebo-azacitidine.
View Article and Find Full Text PDFGuadecitabine is a novel hypomethylating agent (HMA) resistant to deamination by cytidine deaminase. Patients with relapsed/refractory acute myeloid leukemia (AML) were randomly assigned to guadecitabine or a preselected treatment choice (TC) of high-intensity chemotherapy, low-intensity treatment with HMAs or low-dose cytarabine, or best supportive care (BSC). The primary end point was overall survival (OS).
View Article and Find Full Text PDFArticle Synopsis
- Researchers created AI-based prediction models using data from 3,687 acute myeloid leukemia patients, focusing on two treatment types: intensive chemotherapy and azacitidine.
- A multilayer perceptron neural network demonstrated prediction accuracies of 68.5% for intensive chemotherapy patients and 62.1% for those treated with azacitidine.
- The Boruta algorithm effectively identified key diagnostic features needed for predictions, streamlining the complexity of data analysis for hematologists and potentially improving treatment decisions.